Disparity between improvement in left ventricular function and changes in clinical status and exercise capacity during chronic enoximone therapy
- 1 May 1989
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 117 (5) , 1092-1098
- https://doi.org/10.1016/0002-8703(89)90867-3
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Central and regional hemodynamic effects of oral enoximone in congestive heart failure: A double-blind, placebo-controlled studyAmerican Heart Journal, 1988
- Pharmacology of enoximoneThe American Journal of Cardiology, 1987
- Potential mechanisms of improved left ventricular function with enoximone in severe congestive heart failureThe American Journal of Cardiology, 1987
- Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathyThe American Journal of Cardiology, 1986
- MDL 17,043 therapy in severe congestive heart failure: Characterization of the early and late hemodynamic, pharmacokinetic, hormonal and clinical responseJournal of the American College of Cardiology, 1985
- Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patientsJournal of the American College of Cardiology, 1984
- Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failureJournal of the American College of Cardiology, 1984
- Acute hemodynamic effect of oral MDL 17,043 in severe congestive heart failureThe American Journal of Cardiology, 1984
- Biochemical Studies on the Mechanism of Cardiotonic Activity of MDL 17,043Journal of Cardiovascular Pharmacology, 1982
- Cardiovascular Properties of a New Cardiotonic AgentJournal of Cardiovascular Pharmacology, 1982